论文部分内容阅读
目的:回顾性研究177例Ⅱ期乳腺癌患者术后辅助治疗是否规范对预后的影响。方法:纳入2000年1月至2005年12月在我院行术后辅助治疗且符合条件的177例乳腺癌患者的临床以及病理资料,探讨患者术后辅助治疗、年龄、绝经状况、淋巴结清扫、TNM分期、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)、初发到治疗的时间、术式、病理类型、手术地点等与预后的相关性。结果:本组病例中位随访时间为62个月,随访率为82.49%,其中仅53例患者(29.94%)接受了规范辅助治疗。术后辅助治疗规范组与非规范组的5年总生存率分别为98.11%和93.58%,10年总生存率分别为80.66%和61.57%,两组之间存在统计学差异(P<0.05)。此外,与Ⅱ期乳腺癌患者预后有关的独立因素还包括绝经状况、HER-2状态(P<0.05),而年龄、淋巴结清扫个数、TNM分期、初发到治疗时间、病理类型不能成为影响患者预后的独立因素(P>0.05)。结论:术后规范辅助治疗、绝经状况及HER-2与Ⅱ期乳腺癌患者的预后密切相关。
Objective: To retrospectively study the effect of postoperative adjuvant therapy on the prognosis of 177 patients with stage Ⅱ breast cancer. Methods: The clinical and pathological data of 177 patients with breast cancer undergoing postoperative adjuvant therapy from January 2000 to December 2005 in our hospital were enrolled in this study. The postoperative adjuvant therapy, age, menopausal status, lymph node dissection, TNM staging, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), time between initial presentation and treatment, procedure, pathological type, Relevance. Results: The median follow-up time was 62 months. The follow-up rate was 82.49%. Only 53 patients (29.94%) received standardized adjuvant therapy. The 5-year overall survival rates were 98.11% and 93.58% in the adjuvant therapy and non-canonical groups, respectively. The 10-year overall survival rates were 80.66% and 61.57%, respectively. There was a significant difference between the two groups (P <0.05) . In addition, independent factors associated with the prognosis of patients with stage II breast cancer include menopausal status and HER-2 status (P <0.05), while age, number of lymph node dissections, TNM stage, initial to treatment time, pathological type can not be affected Independent prognosis of patients (P> 0.05). Conclusion: Postoperative adjuvant therapy, menopausal status and prognosis of patients with stage Ⅱ breast cancer are closely related to HER-2.